Sector portfolio · VC firm · United States
Mission Bay Capital's Biotech portfolio
Mission Bay Capital has backed 10 Biotech startups in rounds we track, $1.4B between them, shown by the stage each has reached. The best-funded is Atreca.
Funding by segment
- Series C and later$1.3B8
- Series B$74M2
Where they are based
- United States10$1.4B
United StatesFounded
2 without a founding year on record.
Total raised
- Under $1M0
- $1M to $10M0
- $10M to $50M1
- $50M to $250M8
- $250M to $1B1
- $1B and over0
Each dot is a startup: the year it was founded across, the total it has raised up (each line is ten times the one below). Pick a segment to pick it out.
8 of 10 startups shown; the rest have no founding year or amount on record.
- 1 to 2
- 3 to 7
- 8 to 24
- 25 to 99
- 100 and more
- United States10
Startups by country, 1 country in all.
Segment by segment
Series C and later
8 startups · $1.3B raised
- AAtrecaAtreca develops a technology to identify the set of antibodies produced during an immune response, without prior knowledge of an antigen.United States$313M
AlectorAlector is a biopharmaceutical company that develops therapies for the treatment of neurodegeneration diseases.United States$215M
Circle PharmaCircle Pharma is a provider of a macrocycle development platform intended to provide macrocyclic peptides.United States$187M
GlycomineGlycomine is an early-stage biotech working on replacement therapies for rare diseases.United States$160M- STSiteOne TherapeuticsUnited States$119M
Calithera BiosciencesCalithera Biosciences is a pharmaceutical company developing novel small molecule therapeutics for the treatment of cancer.United States$115M
Effector TherapeuticsEffector Therapeutics is an early-stage company focused on the discovery and development of small molecule cancer therapeutics.United States$99M
Vivace TherapeuticsVivace Therapeutics is a venture-backed start-up dedicated to discovering and developing cancer therapeutics by targeting a novel pathway.United States$75M
Series B
2 startups · $74M raised
- PPionyrUnited States$62M
Redwood BioscienceRedwood Bioscience is utilizing precision protein-chemical engineering to develop optimized and novel biotherapeutics.United States$12M
How this map is made. Every startup here works in Biotech and has raised money in a round we track that names Mission Bay Capital as an investor. Each sits under the stage of its latest round. Rebuilt nightly; updated 15 November 2026.
More portfolio maps
All portfoliosRaising from investors like Mission Bay Capital?
Find the investors who back startups like yours, with their cheques, rounds and partners, in the app with filters, lists and exports.